| [1] Scott A M, Wolchok J D, Old L J. Antibody therapy of cancer. Nature reviews Cancer, 2012, 12(4):278-287.
[2] Marasco W A, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnology, 2007, 25(12):1421-1434.
[3] Chan A C, Carter P J. Therapeutic antibodies for autoimmunity and inflammation. Nature Reviews Immunology, 2010, 10(5):301-316.
[4] Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. mAbs, 2011, 3(3):243-252.
[5] Grevys A, Bern M, Foss S, et al. Fc Engineering of Human IgG1 for altered binding to the neonatal Fc receptor affects Fc effector functions. Journal of Immunology, 2015, 194(11):5497-508.
[6] Tabrizi M A, Tseng C M, Roskos L K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discovery Today, 2006, 11(1-2):81-88.
[7] Morell A, Terry W D, Waldmann T A. Metabolic properties of IgG subclasses in man. The Journal of Clinical Investigation, 1970, 49(4):673-680.
[8] Roopenian D C, Akilesh S. FcRn:the neonatal Fc receptor comes of age. Nature reviews Immunology, 2007, 7(9):715-725.
[9] Popov S, Hubbard J G, Kim J, et al. The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn. Molecular Immunology, 1996, 33(6):521-530.
[10] Ober R J, Martinez C, Lai X, et al. Exocytosis of IgG as mediated by the receptor, FcRn:an analysis at the single-molecule level. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(30):11076-11081.
[11] Li B, Tesar D, Boswell C A, et al. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. mAbs, 2014, 6(5):1255-1264.
[12] Datta-Mannan A, Lu J, Witcher D R, et al. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. mAbs, 2015, 7(6):1084-1093.
[13] Sharma V K, Patapoff T W, Kabakoff B, et al. In silico selection of therapeutic antibodies for development:viscosity, clearance, and chemical stability. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111(52):18601-18606.
[14] Hotzel I, Theil F P, Bernstein L J, et al. A strategy for risk mitigation of antibodies with fast clearance. mAbs, 2012, 4(6):753-760.
[15] Wang W, Lu P, Fang Y, et al. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metabolism and Disposition:the Biological Fate of Chemicals, 2011, 39(9):1469-1477.
[16] Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1:a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Journal of Immunology, 2010, 184(4):1968-1976.
[17] Stracke J, Emrich T, Rueger P, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. mAbs, 2014, 6(5):1229-1242.
[18] Wang W, Vlasak J, Li Y, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Molecular Immunology, 2011, 48(6-7):860-866.
[19] Goetze A M, Liu Y D, Zhang Z, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology, 2011, 21(7):949-959.
[20] Bumbaca D, Boswell C A, Fielder P J, et al. Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics. The AAPS Journal, 2012, 14(3):554-558.
[21] Burmeister W P, Huber A H, Bjorkman P J. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature, 1994, 372(6504):379-383.
[22] Junghans R P, Anderson C L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93(11):5512-5516.
[23] Dall'Acqua W F, Woods R M, Ward E S, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor:biological consequences. Journal of Immunology, 2002, 169(9):5171-5180.
[24] Ghetie V, Popov S, Borvak J, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnology, 1997, 15(7):637-640.
[25] Ober R J, Radu C G, Ghetie V, et al. Differences in promiscuity for antibody-FcRn interactions across species:implications for therapeutic antibodies. International Immunology, 2001, 13(12):1551-1559.
[26] Haraya K, Tachibana T, Nanami M, et al. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2014, 44(12):1127-1134.
[27] Proetzel G, Roopenian D C. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods (San Diego, Calif), 2014, 65(1):148-153.
[28] Shields R L, Namenuk A K, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RⅡ, Fc gamma RⅢ, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. The Journal of Biological Chemistry, 2001, 276(9):6591-604.
[29] Yeung Y A, Leabman M K, Marvin J S, et al. Engineering human IgG1 affinity to human neonatal Fc receptor:impact of affinity improvement on pharmacokinetics in primates. Journal of Immunology, 2009, 182(12):7663-7671.
[30] Hinton P R, Johlfs M G, Xiong J M, et al. Engineered human IgG antibodies with longer serum half-lives in primates. The Journal of Biological Chemistry, 2004, 279(8):6213-6216.
[31] Hinton P R, Xiong J M, Johlfs M G, et al. An engineered human IgG1 antibody with longer serum half-life. The Journal of Immunology, 2006, 176(1):346-356.
[32] Zalevsky J, Chamberlain A K, Horton H M, et al. Enhanced antibody half-life improves in vivo activity. Nature Biotechnology, 2010, 28(2):157-159.
[33] Monnet C, Jorieux S, Souyris N, et al. Combined glyco-and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. mAbs, 2014, 6(2):422-436.
[34] Monnet C, Jorieux S, Urbain R, et al. Selection of IgG variants with increased FcRn binding using random and directed mutagenesis:impact on effector functions. Frontiers in Immunology, 2015, 6(39.
[35] Borrok M J, Wu Y, Beyaz N, et al. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. The Journal of Biological Chemistry, 2015, 290(7):4282-4290.
[36] Datta-Mannan A, Wroblewski V J. Application of FcRn binding assays to guide mAb development. Drug Metabolism and Disposition:the Biological Fate of Chemicals, 2014, 42(11):1867-1872.
[37] Ward E S, Devanaboyina S C, Ober R J. Targeting FcRn for the modulation of antibody dynamics. Molecular Immunology, 2015, 67(2 Pt A):131-141.
[38] Dall'Acqua W F, Kiener P A, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). The Journal of Biological Chemistry, 2006, 281(33):23514-23524.
[39] Datta-Mannan A, Witcher D R, Tang Y, et al. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor:relationship to pharmacokinetics in mice and primates. Drug Metabolism and Disposition:the Biological Fate of Chemicals, 2007, 35(1):86-94.
[40] Datta-Mannan A, Witcher D R, Tang Y, et al. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. The Journal of Biological Chemistry, 2007, 282(3):1709-1717.
[41] Yeung Y A, Wu X, Reyes A E, 2nd, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Research, 2010, 70(8):3269-3277.
[42] Zheng Y, Scheerens H, Davis J C, Jr., et al. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study. Clinical Pharmacology and Therapeutics, 2011, 89(2):283-290.
[43] Datta-Mannan A, Chow C K, Dickinson C, et al. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metabolism and Disposition:the Biological Fate of Chemicals, 2012, 40(8):1545-1555.
[44] Robbie G J, Criste R, Dall'acqua W F, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrobial Agents and Chemotherapy, 2013, 57(12):6147-6153.
[45] Burvenich I J, Farrugia W, Lee F T, et al. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. mAbs, 2016, 8(4):775-786.
[46] Igawa T, Tsunoda H, Tachibana T, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Engineering, Design & Selection:PEDS, 2010, 23(5):385-392.
[47] Datta-Mannan A, Thangaraju A, Leung D, et al. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. mAbs, 2015, 7(3):483-493.
[48] Schoch A, Kettenberger H, Mundigl O, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(19):5997-6002.
[49] Kelly R L, Yu Y, Sun T, et al. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. mAbs, 2016, 8(7):1269-1275.
[50] Bumbaca Yadav D, Sharma V K, Boswell C A, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. The Journal of Biological Chemistry, 2015, 290(50):29732-29741.
[51] Boswell C A, Tesar D B, Mukhyala K, et al. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjugate Chemistry, 2010, 21(12):2153-2163.
[52] Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VⅢ cofactor activity. PLoS One, 2013, 8(2):e57479.
[53] Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VⅢ hemostatic activity in a hemophilia A model. Nature Medicine, 2012, 18(10):1570-1574.
[54] Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nature Biotechnology, 2010, 28(11):1203-1207.
[55] Igawa T, Haraya K, Hattori K. Sweeping antibody as a novel therapeutic antibody modality capable of eliminating soluble antigens from circulation. Immunological Reviews, 2016, 270(1):132-151.
[56] Igawa T, Mimoto F, Hattori K. pH-dependent antigen-binding antibodies as a novel therapeutic modality. Biochimica et Biophysica Acta, 2014, 1844(11):1943-1950.
[57] Chaparro-Riggers J, Liang H, DeVay R M, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. The Journal of Biological Chemistry, 2012, 287(14):11090-11097.
[58] Henne K R, Ason B, Howard M, et al. Anti-PCSK9 antibody pharmacokinetics and low-density lipoprotein-cholesterol pharmacodynamics in nonhuman primates are antigen affinity-dependent and exhibit limited sensitivity to neonatal Fc receptor-binding enhancement. The Journal of Pharmacology and Experimental the Rapeutics, 2015, 353(1):119-131.
[59] Murtaugh M L, Fanning S W, Sharma T M, et al. A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches. Protein Science:a Publication of the Protein Society, 2011, 20(9):1619-1631.
[60] Schroter C, Gunther R, Rhiel L, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. mAbs, 2015, 7(1):138-151.
[61] Bonvin P, Venet S, Fontaine G, et al. De novo isolation of antibodies with pH-dependent binding properties. mAbs, 2015, 7(2):294-302.
[62] Hironiwa N, Ishii S, Kadono S, et al. Calcium-dependent antigen binding as a novel modality for antibody recycling by endosomal antigen dissociation. mAbs, 2016, 8(1):65-73.
[63] Chen W, Bardhi A, Feng Y, et al. Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. mAbs, 2016, 8(4):761-774.
[64] Lyon R P, Bovee T D, Doronina S O, et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nature Biotechnology, 2015, 33(7):733-735.
[65] Igawa T, Maeda A, Haraya K, et al. Engineered monoclonal antibody with novel antigen-sweeping activity in vivo. PLoS One, 2013, 8(5):e63236. |
